Author: Ola Myklebost

Vokste opp på Eiksmarka og Haslum i Bærum, bodde 30 år på Trollåsen i Oppegård, bor nå på Nordnes i Bergen

Publications 2026

Moura DS, Lopez-Marti JM, Tawbi HA, Keung E, Wani KM, Lazar AJ, Wang WL, Ingram DR, Meza-Zepeda LA, Myklebost O, Burgess MA, Mondaza-Hernandez JL, Hindi N, Martín-Broto J (2026) Validation of a seven-gene predictive SIGNature for the efficacy of Immuno-Oncology PD-1 inhibitors in Sarcoma patients (SIGNIOS). Clin Cancer Res doi: 10.1158/1078-0432.CCR-25-2580

Mensali N, Joaquina S, de Montlaur C, Casey NP, Nesset TO, Myhre MR, Myklebost O, McCormack E, Passetto A, Gunnes MW, Gelebart P, Inderberg EM, Wälchli S (2026) Pre-clinical validation of OSCAR-3 mRNA-based CAR T cells for targeting Osteosarcomas. Cytotherapy doi: https://doi.org/10.1016/j.jcyt.2026.102930

Giordano G, Tucciarello C, Gucciardo G, Russo N, Wesche J, Myklebost O, Meza-Zepeda LA, Merlini A, Cutrupi S, Sangiolo D, Isella C, Sapino A, Marchiò C, Grignani G, Pignochino Y (2026) The paracrine ephrin A4/BMP4 feed-forward loop sustains a tumor–CAF vicious cycle in osteosarcoma. Cell Communication and Signaling In press.

    Publications 2025

    Naolou T, Schadzek N, Pepelanova I, Frommer M, Lötz F, Sauheitl L, Myklebost O, Lee-Thedieck C (2025) Development of a 3D-printable Nanohydroxyapatite / Methacrylated Gelatine-based Nanocomposite Hydrogel Promoting Osteogenic Differentiation. Biofabrication  doi 10.1088/1758-5090/adbb90

     

    da Silva Moura DS, Lopez-Marti JM, Tawbi HA, Keung E, Wani KM, Lazar AJ, Wang WL, Ingram DR, Meza-Zepeda LA, Myklebost O, Burgess MA, Mondaza-Hernandez JL, Hindi N (2025) Validation of a seven-gene predictive SIGNature for the efficacy of Immuno-Oncology PD-1 inhibitors in Sarcoma patients (SIGNIOS). Clin Cancer Res In press

    [:en]Publications 2024[:]

    [:nb][nb:] Myklebust J, Bai B, Wise J, Vodák D, Nakken S, Sharma A, Blaker Y, Brodtkorb M, Hilden V, Trøen G, Ren W, Lorenz S, Lawrence M, Myklebost O, Kimby E, Pan-Hammarström Q, Steen C, Meza-Zepeda LA, Beiske K, Smeland E, Hovig E, Lingjærde O, Holte H (2024) Multi-omics profiling of longitudinal samples reveals early genomic changes in follicular lymphoma.   Blood Cancer Journal 14:147. doi: 10.1038/s41408-024-01124-5.

    Ranji P, Jonasson E, Andersson L, Filges S, Santamaría ML, Vannas C, Dolatabadi S, Gustafsson A, Myklebost O, Håkansson J, Fagman H, Landberg G, Åman P, Ståhlberg A (2024) Deciphering the role of FUS::DDIT3 expression and tumor microenvironment in myxoid liposarcoma development. J Transl Med 10.1186/s12967-024-05211-w

    Sveen A, Johannessen B, Klokkerud SM, Kraggerud SM, Meza-Zepeda LA, Bjørnslett M, Bischof K, Myklebost O, Taskén K, Skotheim RI, Dørum A, Davidson B, Lothe RA (2024). Evolutionary mode and timing of dissemination of high-grade serous carcinomas. JCI Insight. e170423. doi: 10.1172/jci.insight.170423

    Zhou Y, Ray PS, Zhu J, Stein F, Rettel M, Sekaran T, Sahadevan S, Perez-Perri JI, Roth EK, Myklebost O, Meza-Zepeda LA, von Deimling A, Fu C, Brosig AN, Boye K, Nathrath M, Blattmann C, Lehner B, Hentze MW, Kulozik AE (2024) Systematic analysis of RNA-binding proteins identifies targetable therapeutic vulnerabilities in osteosarcoma Nat Commun DOI: 10.1038/s41467-024-47031-y[:en]Myklebust J, Bai B, Wise J, Vodák D, Nakken S, Sharma A, Blaker Y, Brodtkorb M, Hilden V, Trøen G, Ren W, Lorenz S, Lawrence M, Myklebost O, Kimby E, Pan-Hammarström Q, Steen C, Meza-Zepeda LA, Beiske K, Smeland E, Hovig E, Lingjærde O, Holte H (2024) Multi-omics profiling of longitudinal samples reveals early genomic changes in follicular lymphoma.   Blood Cancer Journal 14:147. doi: 10.1038/s41408-024-01124-5.

    Ranji P, Jonasson E, Andersson L, Filges S, Santamaría ML, Vannas C, Dolatabadi S, Gustafsson A, Myklebost O, Håkansson J, Fagman H, Landberg G, Åman P, Ståhlberg A (2024) Deciphering the role of FUS::DDIT3 expression and tumor microenvironment in myxoid liposarcoma development. J Transl Med 10.1186/s12967-024-05211-w

    Sveen A, Johannessen B, Klokkerud SM, Kraggerud SM, Meza-Zepeda LA, Bjørnslett M, Bischof K, Myklebost O, Taskén K, Skotheim RI, Dørum A, Davidson B, Lothe RA (2024). Evolutionary mode and timing of dissemination of high-grade serous carcinomas. JCI Insight. e170423. doi: 10.1172/jci.insight.170423

    Zhou Y, Ray PS, Zhu J, Stein F, Rettel M, Sekaran T, Sahadevan S, Perez-Perri JI, Roth EK, Myklebost O, Meza-Zepeda LA, von Deimling A, Fu C, Brosig AN, Boye K, Nathrath M, Blattmann C, Lehner B, Hentze MW, Kulozik AE (2024) Systematic analysis of RNA-binding proteins identifies targetable therapeutic vulnerabilities in osteosarcoma Nat Commun DOI: 10.1038/s41467-024-47031-y[:]

    [:nb]Publications 2023[:]

    [:nb]Anzar, I., B. Malone, P. Samarakoon, I. Vardaxis, B. Simovski, H. Fontenelle, L. A. Meza-Zepeda, R. Stratford, E. Keung, M. Burgess, H. A. Tawbi, O. Myklebost and T. Clancy (2023). «The interplay between neoantigens and immune cells in sarcomas treated with checkpoint inhibition.» Front. Immunol. doi: 10.3389/fimmu.2023.1226445

    Ballinger ML, Pattnaik S, Mundra PA, Zaheed M, Rath E, Priestley P, Baber J, Ray-Coquard I, Isambert N, Causeret S, van der Graaf WTA, Puri A, Duffaud F, Le Cesne A, Seddon B, Chandrasekar C, Schiffman JD, Brohl AS, James PA, Kurtz JE, Penel N, Myklebost O, Meza-Zepeda LA, Pickett H, Kansara M, Waddell N, Kondrashova O, Pearson JV, Barbour JV, Li S, Nguyen TL, Green MJ, Kaplan W, Ravishankar S, Copty J, Powell JE, Ahn JH, Kim JU, Randall RL, Tucker K, Judson I, Sarin R, Haber M, Marshall G, Cairns MJ, Blay JY, Thomas DM (2023) Heritable defects in telomere and mitotic function selectively predispose to sarcomas Science doi: 10.1126/science.abj4784

    Namløs HM, Khelik K, Nakken S, Vodák D, Hovig E, Myklebost O, Boye K, Meza-Zepeda LA (2023) Chromosomal instability and a deregulated cell cycle are intrinsic features of high-risk gastrointestinal stromal tumours with a metastatic potential. Molecular Oncology doi:10.1002/1878-0261.13514 [:en][En:]
    Anzar, I., B. Malone, P. Samarakoon, I. Vardaxis, B. Simovski, H. Fontenelle, L. A. Meza-Zepeda, R. Stratford, E. Keung, M. Burgess, H. A. Tawbi, O. Myklebost and T. Clancy (2023). «The interplay between neoantigens and immune cells in sarcomas treated with checkpoint inhibition.» Front. Immunol. doi: 10.3389/fimmu.2023.1226445

    Ballinger ML, Pattnaik S, Mundra PA, Zaheed M, Rath E, Priestley P, Baber J, Ray-Coquard I, Isambert N, Causeret S, van der Graaf WTA, Puri A, Duffaud F, Le Cesne A, Seddon B, Chandrasekar C, Schiffman JD, Brohl AS, James PA, Kurtz JE, Penel N, Myklebost O, Meza-Zepeda LA, Pickett H, Kansara M, Waddell N, Kondrashova O, Pearson JV, Barbour JV, Li S, Nguyen TL, Green MJ, Kaplan W, Ravishankar S, Copty J, Powell JE, Ahn JH, Kim JU, Randall RL, Tucker K, Judson I, Sarin R, Haber M, Marshall G, Cairns MJ, Blay JY, Thomas DM (2023) Heritable defects in telomere and mitotic function selectively predispose to sarcomas Science doi: 10.1126/science.abj4784

    Namløs HM, Khelik K, Nakken S, Vodák D, Hovig E, Myklebost O, Boye K, Meza-Zepeda LA (2023) Chromosomal instability and a deregulated cell cycle are intrinsic features of high-risk gastrointestinal stromal tumours with a metastatic potential. Molecular Oncology doi:10.1002/1878-0261.13514 [En:]

    [:]

    [:en]Pioneer postdoc announcement[:]

    UNIVERSITY OF BERGEN

    Postdoctoral Research Fellow in pediatric cancer biology

    UiB – Knowledge that shapes society

    Through robust and close interaction with the world around us – globally, nationally and locally – we shall be instrumental in building a society based on knowledge, skills and attitudes.

    Do you want to take part in shaping the future?

    Postdoctoral Research Fellow position

    Funded by a highly competitive Pioneer Grant for novel and game-changing projects.

    At the Faculty of Medicine, Department of Clinical Science, a full-time (100 %) position as Postdoctoral Research Fellow is available for a period of two (2) years. The position is part of the project, ”KidImmune – Autoimmune mechanisms in pediatric cancer”, financed by the Norwegian Cancer Society Pioneer Program. See http://kidimmune.no for more information.

    Our small, enthusiastic group consisting of Ola Myklebost, an experienced cell biologist and cancer researcher, and research fellow Anastassia Serguienko, who made the entirely novel discoveries on which this project is built, has the focus completely on this project. Our findings open up a Pandora’s box of fascinating questions that need answers. We have laid a solid foundation of clinical sample collections, proteomic data, technologies, and cell models to give the candidate a flying start.

    We have access to expert in-house core facilities for genomics, proteomics, flow cytometry and advanced microscopy.

    About the project/work tasks:

    • Investigations on how patient autoantibodies may influence important processes in normal and cancer cells in culture
    • Using immunohistochemistry, advanced microscopy, flow cytometry, protein chemistry, and various functional assays

    Qualifications and personal qualities:

    • The applicant must hold a Norwegian PhD or an equivalent degree or have submitted the doctoral thesis prior to the application deadline. It is a condition of employment that the PhD has been awarded at the latest within 31.12.2022
    • Work independently and in a structured manner and have good ability to communicate and cooperate.
    • Proficiency in both written and oral English is required. Proficiency in Norwegian would be an advantage
    • Special requirements for the position: Project experience from mammalian molecular and cell biology is required, including cellular structure and function or advanced human immunology. Competence in excess of course experience in immunology, protein chemistry and function, advanced cell microscopy, or cancer biology would be an advantage

    About the position of postdoctoral research fellow:

    The position of postdoctoral research fellow is a fixed-term appointment with the primary objective of qualifying the appointee for work in top academic positions. Postdoctoral fellowships are fixed term positions. You can not be employed as a postdoctoral fellow for more than one three-year period at the same institution.

    We can offer:

    Your application must include:

    • A brief account of the applicant`s research interests and motivation for applying for the position
    • Transcripts and diplomas (applicants with education from other countries than Norway must enclose witnessed diplomas in both the original language and authorized translations) and documentation of submitted doctoral thesis
    • Complete list of publications
    • Publications (pdf) it is important that each of the scholarly works on which the committee should place special emphasis, is attached in its entirety
    • Two referees (name and contact information)

    General information:

    For further information please contact prof. Ola Myklebost, e-mail: ola.myklebost@uib.no phone: +47 55974573 / +47 90087139

    The state labour force shall reflect the diversity of Norwegian society to the greatest extent possible. People with immigrant backgrounds and people with disabilities are encouraged to apply for the position.

    The University of Bergen applies the principle of public access to information when recruiting staff for academic positions.

    Information about applicants may be made public even if the applicant has asked not to be named on the list of persons who have applied. The applicant must be notified if the request to be omitted is not met.

    Further information about our employment process can be found here.

    [:nb]Publications 2022[:]

    [:nb]Namløs H, Skårn M, Ahmed D, Grad I, Andresen K, Kresse S, Serra M, Scotlandi K, Llombart-Bosch A, Myklebost O, Lind G, Meza-Zepeda LA (2022) miR-486 expression is regulated by DNA methylation in osteosarcoma BMC Genomics 23:142. doi: 10.1186/s12864-022-08346-6

    Misund K, Hofste op Bruinink D, Coward E, Hoogenboezem RM, Rustad EH, Sanders MA, Rye M, Sponaas AM, van der Holt B, Zweegman S, Hovig E, Meza-Zepeda LA, Sundan A, Myklebost O, Sonneveld P, Waage A. (2022) Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence Leukemia 10.1038/s41375-022-01597-y 

    Venizelos A, Engebrethsen C, Deng W, Geisler J, Geisler S, Iversen GT, Aas T, Aase HS, Seyedzadeh M, Steinskog ES, Myklebost O, Nakken S, Vodak D, Hovig E, Meza-Zepeda LA, Lønning PE, Knappskog S, Eikesdal HP (2022) Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel  monotherapy Genome Med DOI: doi: 10.1186/s13073-022-01090-2  [:en]Namløs H, Skårn M, Ahmed D, Grad I, Andresen K, Kresse S, Serra M, Scotlandi K, Llombart-Bosch A, Myklebost O, Lind G, Meza-Zepeda LA (2022) miR-486 expression is regulated by DNA methylation in osteosarcoma BMC Genomics 23:142. doi: 10.1186/s12864-022-08346-6

    Misund K, Hofste op Bruinink D, Coward E, Hoogenboezem RM, Rustad EH, Sanders MA, Rye M, Sponaas AM, van der Holt B, Zweegman S, Hovig E, Meza-Zepeda LA, Sundan A, Myklebost O, Sonneveld P, Waage A. (2022) Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence Leukemia 10.1038/s41375-022-01597-y 

    Venizelos A, Engebrethsen C, Deng W, Geisler J, Geisler S, Iversen GT, Aas T, Aase HS, Seyedzadeh M, Steinskog ES, Myklebost O, Nakken S, Vodak D, Hovig E, Meza-Zepeda LA, Lønning PE, Knappskog S, Eikesdal HP (2022) Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel  monotherapy Genome Med DOI: doi: 10.1186/s13073-022-01090-2 

    [:]

    KidImmune, – Autoimmune mechanisms in pediatric cancer

    This main project is now headed by Anastassia Serguienko, funded by a researcher grant to her from the Pediatric Cancer Association, together with Jeetesh Sharma, who got the postdoc Pioneer grant from the Cancer Society, and from 2024 a project grant from the MOHN Foundation, which also funds a PhD grant togehther with UiB for Ronas Shakya in epidemiology.

    Since this project was potentially ground-breaking, we have worked on it quietly for several years. For the first time we presented our data and hypothesis publicly in the New scientific discovery session at the SIOP meeting in Amsterdam 2025. You can read the abstract here.

    At last, our KidImmune Project has come to fruition, and will be published October 14th in Frontiers in Immunology!

    A new study in Frontiers in Immunology found that autoantibodies against DNA repair proteins are shared by cancer patients and by healthy children who were later diagnosed with cancer years afterward. This opens a new angle on pediatric cancer etiology, beyond the classical genetic-mutation view.
    Read the full article: https://lnkd.in/eWsRRs4D

    For 6 years we have pursued the surprising discovery made while using human proteome microarrays to profile autoantibodies in sarcoma patients, that children with various types of cancer have many autoantibodies against DNA repair proteins. These proteins resemble typical tumour suppressor proteins involved in hereditary cancer syndromes, but are not significantly mutated in pediatric cancers, thus they are not expected to be cancer-associated neoantigens.

    This led to our hypothesis that they could be involved in the etiology of cancer. We observed, as others have previously reported, that such antibodies can enter a fraction of live cells and even their nuclei, and thus might inhibit DNA repair and induce mutations.

    By analysing autoantibody profiles in serum samples collected at school age in children from the Born in Bradford and ALSPAC cohorts, we found in those 30 who got cancer before 26 years of age a similar enrichment in DNA repair autoantigens that we found in our pediatric cancer patients.

    We observe that cells internalizing such antibodies may sequester DNA repair proteins in the cytoplasm, which could prevent their activity in the nucleus, and are pursuing investigations of the influence on DNA repair activity.

    We thus propose that autoantibodies of this kind can attenuate or impair DNA repair and lead to initiation of cancer, although it will need more research to prove direct causality.

    Publications 2021

    Georgiesh T, Namløs HM, Sharma N, Lorenz S, Myklebost O, Bjerkehagen B, Meza-Zepeda LA, Boye K (2021) Clinical and molecular implications of NAB2-STAT6 fusion variants in solitary fibrous tumor. Pathology 53:713-719 doi:10.1016/j.pathol.2020.11.010

    Grad I, Hanes R, Ayuda-Durán P, Kuijjer ML, Enserink JM, Meza-Zepeda LA, Myklebost O (2021) Discovery of novel candidates for anti-liposarcoma therapies by medium-scale high-throughput drug screening. PLoS DOI:10.1371/journal.pone.0248140 

    Nakken S, Saveliev V, Hofmann O, Møller P, Myklebost O, Hovig E (2020) Cancer Predisposition Sequencing Reporter (CPSR): a flexible variant report engine for high-throughput germline screening in cancer.  Int J Cancer Vol.149(11), p.1955-1960 doi: 10.1002/ijc.33749 

    Peneder P, Stütz AM, Surdez D, Krumbholz M, Semper S, Chi-card M, Sheffield NC, Pierron G, Lapouble E, Tötzl M, Ergüner B, Barre-ca D, Rendeiro AF, Agaimy A, Boztug H, Engstler G, Dworzak M, Bernkopf M, Taschner-Mandl S, Ambros IM, Myklebost O, Marec-Berard P, Burchill SA, Brennan B, Strauss SJ, Whelan J, Schleiermacher G, Dirksen U, Hutter C, Boye K, Ambros PF, Delattre O, Metzler M, Bock C, Tomazou E (2021) Accurate detection and classification of Ewing sarcoma tumors based on cell-free DNA fragmentation patterns inferred from whole genome sequencing. Nature Communications 28;12(1):3230. doi: 10.1038/s41467-021-23445-w

    Stabell M, Sæther T, Røhr ÅK, Gabrielsen OS, Myklebost O (2021) Methylation-dependent SUMOylation of the architectural transcription factor HMGA2. Biochemical and Biophysical Research Communications, doi: 10.1016/j.bbrc.2021.02.099 

    Sveen A, Johannessen B, Eilertsen IA, Røsok BI, Gulla M, Eide PW, Bruun J, Kryeziu K, Meza-Zepeda LA, Myklebost O, Bjørnbeth BA, Skotheim RI, Nesbakken A, Lothe RA (2021) The expressed mutational landscape of microsatellite stable colorectal cancers. Genome Medicine 13:142. doi: 10.1186/s13073-021-00955-2